Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NvfiledCriticalJanssen Pharmaceutica Nv
Publication of AR059497A1publicationCriticalpatent/AR059497A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
La presente es un método para tratar, prevenir, revertir, detener o inhibir la aparicion, desarrollo y maduracion de ataques o trastornos relacionados con ataques. Más específicamente, la presente refiere a métodos para el uso de derivados de benzo- heteroaril sulfamidas de formula (1) como se describe en la presente para tratar, prevenir, revertir, detener o inhibir terapéutica o profilácticamente la epileptogénesis y la epilepsia.This is a method to treat, prevent, reverse, stop or inhibit the appearance, development and maturation of attacks or disorders related to attacks. More specifically, this refers to methods for the use of benzo-heteroaryl sulfamide derivatives of formula (1) as described herein to treat, prevent, reverse, stop or therapeutically or prophylactically inhibit epileptogenesis and epilepsy.
ARP070100624A2006-02-152007-02-14
USE OF BENZO-HETEROARIL SULFAMIDAS DERIVATIVES IN THE TREATMENT OF ILLNESS / EPILEPTOGENESIS MODIFICATION
AR059497A1
(en)
COMPOSITION, KIT, AND METHODS TO REDUCE A SIDE TREATMENT EFFECT WITH A CALCINEURIN INHIBITOR, TO INCREASE A THERAPEUTIC EFFECT OF A CALCINEURIN INHIBITOR AND TO CHANGE THE CONCENTRATION OF TACROLIMUS OR ANALYLOGAL ANALOGUE
Use of a pegylated variant of igf-1 to treat, prevent a neuromuscular disorder; method for the treatment, prevention and / or delay of a neuromuscular disorder; composition comprising the modified igf-1 variant